Lv1
32 积分 2023-02-08 加入
Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non–Small-Cell Lung Cancer
6小时前
待确认
Prevalence of EGFR Mutations in Patients With Resected Stage I-III NSCLC: Results From the EARLY-EGFR Study
13天前
已完结
Efficacy of Shenyi Capsule Combined with Gefitinib in Treatment of Advanced Non-small Cell Lung Cancer
20天前
已完结
The Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Clinical Stage I Lung Adenocarcinoma
24天前
已完结
Long-term outcomes of neoadjuvant gefitinib in resectable stage II-IIIA non-small cell lung cancer: A phase II, prospective cohort study
1个月前
已完结
[Expert consensus on BRAF inhibitors in the treatment of malignant solid tumors (2024 edition)]
1个月前
已完结
[Consensus on the molecular residual disease testing in solid tumor]
1个月前
已完结
Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
1个月前
已完结
High-Risk Features Associated with Recurrence in Stage I Lung Adenocarcinoma
3个月前
已完结
EP12.01-01 The Safety and Efficacy of Aumolertinib in Advanced NSCLC Patients with EGFRm Who were Intolerant to Osimertinib: A Retrospective Clinical Study
4个月前
已完结
皖公网安备34019202002308
